Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Mindur, John E ^a   Ito, Naoko ^a   Dhib Jalbut, Suhayl ^a   Ito, Kouichi ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NATALIZUMAB; MONOCLONAL ANTIBODY; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SCREENING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; TH1 CELL; TH17 CELL; UPREGULATION; ANIMAL; C57BL MOUSE; CENTRAL NERVOUS SYSTEM; CYTOLOGY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11B; CD4-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHA4BETA1; MACROPHAGES; MICE; MICE, INBRED C57BL;

EID: 84902438804     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099068     Document Type: Article

References (52)

1. McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8: 913-919. (Pubitemid 47300005)
2. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63-66.
3. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr (1993) Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177: 57-68. (Pubitemid 23008085)
4. Engelhardt B, Laschinger M, Schulz M, Samulowitz U, Vestweber D, et al. (1998) The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J Clin Invest 102: 2096-2105. (Pubitemid 29018816)
5. Brocke S, Piercy C, Steinman L, Weissman IL, Veromaa T (1999) Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A 96: 6896-6901. (Pubitemid 29274981)
6. Steinman L (2012) The discovery of natalizumab, a potent therapeutic for multiple sclerosis. J Cell Biol 199: 413-416.
7. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15-23. (Pubitemid 36026342)
8. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
9. Gunnarsson M, Malmestrom C, Axelsson M, Sundstrom P, Dahle C, et al. (2011) Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 69: 83-89.
10. Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, et al. (2011) Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report. Neurol Sci 31 Suppl 3: 317-320.
11. Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, et al. (2012) Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Mult Scler 18: 1760-1767.
12. Fitzner D, Simons M (2010) Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies. Curr Neuropharmacol 8: 305-315.
13. Theien BE, Vanderlugt CL, Eagar TN, Nickerson-Nutter C, Nazareno R, et al. (2001) Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 107: 995-1006. (Pubitemid 32323409)
14. Kerfoot SM, Kubes P (2002) Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J Immunol 169: 1000-1006. (Pubitemid 34753459)
15. Theien BE, Vanderlugt CL, Nickerson-Nutter C, Cornebise M, Scott DM, et al. (2003) Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 102: 4464-4471. (Pubitemid 37494111)
16. Kerfoot SM, Norman MU, Lapointe BM, Bonder CS, Zbytnuik L, et al. (2006) Reevaluation of P-selectin and alpha 4 integrin as targets for the treatment of experimental autoimmune encephalomyelitis. J Immunol 176: 6225-6234.
17. Rothhammer V, Heink S, Petermann F, Srivastava R, Claussen MC, et al. (2011) Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE. J Exp Med 208: 2465-2476.
18. Ji N, Rao N, Guentzel NM, Arulanandam BP, Forsthuber TG (2011) Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin. J Immunol 186: 2750-2756.
19. Wright E, Rahgozar K, Hallworth N, Lanker S, Carrithers MD (2013) Epithelial V-like antigen mediates efficacy of anti-alpha(4) integrin treatment in a mouse model of multiple sclerosis. PLoS One 8: e70954.
20. Bullard DC, Hu X, Schoeb TR, Axtell RC, Raman C, et al. (2005) Critical requirement of CD11b (Mac-1) on T cells and accessory cells for development of experimental autoimmune encephalomyelitis. J Immunol 175: 6327-6333. (Pubitemid 41598872)
21. Tuohy VK, Yu M, Yin L, Kawczak JA, Johnson JM, et al. (1998) The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 164: 93-100. (Pubitemid 28438399)
22. Berard JL, Wolak K, Fournier S, David S (2010) Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 58: 434-445.
23. Cannella B, Gaupp S, Tilton RG, Raine CS (2003) Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis. J Neurosci Res 71: 407-416. (Pubitemid 36159499)
24. Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, et al. (2007) GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 178: 39-48. (Pubitemid 46039660)
25. El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, et al. (2011) The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12: 568-575.
26. Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, et al. (2011) RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12: 560-567.
27. Ponomarev ED, Shriver LP, Dittel BN (2006) CD40 expression by microglial cells is required for their completion of a two-step activation process during central nervous system autoimmune inflammation. J Immunol 176: 1402-1410. (Pubitemid 43134282)
28. Ponomarev ED, Shriver LP, Maresz K, Dittel BN (2005) Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 81: 374-389. (Pubitemid 41359292)
29. Benveniste EN (1997) Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med (Berl) 75: 165-173.
30. Peferoen L, Kipp M, van der Valk P, van Noort JM, Amor S (2013) Review series on immune responses in neurodegenerative diseases: Oligodendrocytemicroglia cross-talk in the CNS. Immunology.
31. Kanwar JR, Kanwar RK, Wang D, Krissansen GW (2000) Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunol Cell Biol 78: 641-645.
32. Bauer J, Bradl M, Hickley WF, Forss-Petter S, Breitschopf H, et al. (1998) T-cell apoptosis in inflammatory brain lesions: destruction of T cells does not depend on antigen recognition. Am J Pathol 153: 715-724. (Pubitemid 28419026)
33. Issazadeh S, Abdallah K, Chitnis T, Chandraker A, Wells AD, et al. (2000) Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. J Clin Invest 105: 1109-1116. (Pubitemid 30217695)
34. Rawji KS, Yong VW (2013) The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin Dev Immunol 2013: 948976.
35. Hiraki K, Park IK, Kohyama K, Matsumoto Y (2009) Characterization of CD8-positive macrophages infiltrating the central nervous system of rats with chronic autoimmune encephalomyelitis. J Neurosci Res 87: 1175-1184.
36. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM (2011) Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 14: 1142-1149.
37. Chuluyan HE, Issekutz AC (1993) VLA-4 integrin can mediate CD11/CD18-independent transendothelial migration of human monocytes. J Clin Invest 92: 2768-2777. (Pubitemid 24006543)
38. Getts DR, Terry RL, Getts MT, Muller M, Rana S, et al. (2012) Targeted blockade in lethal West Nile virus encephalitis indicates a crucial role for very late antigen (VLA)-4-dependent recruitment of nitric oxide-producing macrophages. J Neuroinflammation 9: 246.
39. Hoshino T, Yamada A, Honda J, Imai Y, Nakao M, et al. (1993) Tissue-specific distribution and age-dependent increase of human CD11b+ T cells. J Immunol 151: 2237-2246. (Pubitemid 23235697)
40. Weng NP, Akbar AN, Goronzy J (2009) CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol 30: 306-312.
41. McFarland HI, Nahill SR, Maciaszek JW, Welsh RM (1992) CD11b (Mac-1): a marker for CD8+ cytotoxic T cell activation and memory in virus infection. J Immunol 149: 1326-1333.
42. Wagner C, Hansch GM, Stegmaier S, Denefleh B, Hug F, et al. (2001) The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol 31: 1173-1180.
43. Christensen JE, Andreasen SO, Christensen JP, Thomsen AR (2001) CD11b expression as a marker to distinguish between recently activated effector CD8(+) T cells and memory cells. Int Immunol 13: 593-600. (Pubitemid 32293529)
44. Lin Y, Roberts TJ, Sriram V, Cho S, Brutkiewicz RR (2003) Myeloid marker expression on antiviral CD8+ T cells following an acute virus infection. Eur J Immunol 33: 2736-2743. (Pubitemid 37337139)
45. Kotsougiani D, Pioch M, Prior B, Heppert V, Hansch GM, et al. (2010) Activation of T Lymphocytes in Response to Persistent Bacterial Infection: Induction of CD11b and of Toll-Like Receptors on T Cells. Int J Inflam 2010: 526740.
46. Peguillet I, Milder M, Louis D, Vincent-Salomon A, Dorval T, et al. (2014) High numbers of differentiated effector CD4 T cells are found in cancer patients and correlate with clinical response after neo-adjuvant therapy of breast cancer. Cancer Res.
47. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY (2004) TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A 101: 3029-3034. (Pubitemid 38327729)
48. Chen X, Zhang M, Zhu X, Deng Q, Liu H, et al. (2009) Engagement of Toll-like receptor 2 on CD4(+) T cells facilitates local immune responses in patients with tuberculous pleurisy. J Infect Dis 200: 399-408.
49. Imanishi T, Hara H, Suzuki S, Suzuki N, Akira S, et al. (2007) Cutting edge: TLR2 directly triggers Th1 effector functions. J Immunol 178: 6715-6719. (Pubitemid 46847393)
50. Reynolds JM, Pappu BP, Peng J, Martinez GJ, Zhang Y, et al. (2010) Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 32: 692-702.
51. Miranda-Hernandez S, Gerlach N, Fletcher JM, Biros E, Mack M, et al. (2011) Role for MyD88, TLR2 and TLR9 but not TLR1, TLR4 or TLR6 in experimental autoimmune encephalomyelitis. J Immunol 187: 791-804.
52. Quandt JA, Huh J, Baig M, Yao K, Ito N, et al. (2012) Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. J Immunol 189: 2897-2908.